Answers are grounded in this paper and cite their sources.
Vildagliptin is one of the Dipeptidyl Peptidase-4 (DPP-4) inhibitors. It is used as a novel oral anti-diabetic drug for the treatment of Type 2 Diabetes Mellitus (T2DM) with significant control of glycated hemoglobin and a lower incidence of hypoglycemia or weight gain.
No takes yet. Share an insight, caveat, or question.
Sahar Kamal (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: